Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,HROW,25981000,26582200,592000,,217000,-355000,217000,8164000,11673000,2917000,2917000,,-513000,,,,0,15443000,12526000,3770000,-2700000,,217000,217000,1912000,105382000,28382000,28225000,3000,56252000,26000,200000,-77183000,800000,332000,6304000,10074000,2659000,10851000,40636000,2521000,25813000,3253000,10996000,4496000,4941000,1042000.0,-224000.0,-751000.0,-781000.0,-716000.0,2203000.0,-30000.0,3208000.0,652000.0,-534000.0,-610000.0,3061000.0,-211000.0,,30562000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Harrow Health, Inc.",0.2066328,269543520,40.56,9.337017,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,10.14,1630526402,-0.46000004,10.59,10.75,10.113,140476,NGM,us_market,-4.3396225,10.113 - 10.75,10.6,0.0,0.0,8,11,finmb_21993612,NasdaqGM,"Harrow Health, Inc.",USD,271843,135228,5.4900002,1.1806452,4.65 - 11.24,-1.0999994,-0.09786472,4.65,11.24,1620763200,1636369140,1636718400,27.112299,0.374,0.25,-0.13,-78.00001,1.086,8.7748575,1.3651428,0.15557435,8.403551,1.7364492,0.91,,,11.24,4.65,8.77,8.4,271.84k,135.23k,26.58M,,19.24M,11.20%,57.44%,1.86M,6.3,8.69%,7.01%,1.68M,,,,,,0.00%,,,1:5,"Feb 07, 2013","Dec 30, 2020","Mar 30, 2021",18.60%,8.18%,5.20%,45.32%,52.5M,2.02,30.70%,34.41M,6.35M,9.77M,0.37,,32.12M,1.21,20.77M,74.53,4.03,1.09,2.66M,2.38M,Value,37205,Healthcare,125,8,8,"Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.",Nashville,615 733 4730,TN,2,1609372800,1622505600,7,United States,http://www.harrowinc.com,86400,6,102 Woodmont Boulevard,858 345 1745,Drug Manufacturers—Specialty & Generic,Suite 610
t-1,HROW,24912000,26582200,591000,,1145000,-355000,1149000,7441000,10658000,2626000,2626000,,-673000,,,,4000,14595000,11969000,3937000,-1481000,,1141000,1149000,1939000,104557000,30646000,27183000,66000,57474000,26000,200000,-77400000,800000,332000,4101000,10799000,3898000,11252000,40131000,3820000,28645000,2662000,12378000,3962000,3645000,-2097000.0,-90000.0,-749000.0,-770000.0,-1548000.0,-1426000.0,-29000.0,-566000.0,689000.0,12000.0,-459000.0,1585000.0,-82000.0,8000.0,29332000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Harrow Health, Inc.",0.2066328,269543520,40.56,9.337017,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,10.14,1630526402,-0.46000004,10.59,10.75,10.113,140476,NGM,us_market,-4.3396225,10.113 - 10.75,10.6,0.0,0.0,8,11,finmb_21993612,NasdaqGM,"Harrow Health, Inc.",USD,271843,135228,5.4900002,1.1806452,4.65 - 11.24,-1.0999994,-0.09786472,4.65,11.24,1620763200,1636369140,1636718400,27.112299,0.374,0.25,-0.13,-78.00001,1.086,8.7748575,1.3651428,0.15557435,8.403551,1.7364492,0.91,,,11.24,4.65,8.77,8.4,271.84k,135.23k,26.58M,,19.24M,11.20%,57.44%,1.86M,6.3,8.69%,7.01%,1.68M,,,,,,0.00%,,,1:5,"Feb 07, 2013","Dec 30, 2020","Mar 30, 2021",18.60%,8.18%,5.20%,45.32%,52.5M,2.02,30.70%,34.41M,6.35M,9.77M,0.37,,32.12M,1.21,20.77M,74.53,4.03,1.09,2.66M,2.38M,Value,37205,Healthcare,125,8,8,"Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.",Nashville,615 733 4730,TN,2,1609372800,1622505600,7,United States,http://www.harrowinc.com,86400,6,102 Woodmont Boulevard,858 345 1745,Drug Manufacturers—Specialty & Generic,Suite 610
t-2,HROW,22985000,26582200,670000,,8623000,-347000,8638000,8436000,10703000,1597000,1597000,,-498000,,,,0,14399000,12802000,3696000,7026000,,8623000,8638000,1958000,103798000,34542000,25275000,63000,59470000,26000,200000,-78549000,800000,332000,5527000,13782000,3750000,11718000,40977000,4485000,27739000,3010000,13160000,3974000,5511000,-292000.0,-281000.0,-753000.0,-761000.0,425000.0,1625000.0,-29000.0,2667000.0,712000.0,-133000.0,-96000.0,-6698000.0,-244000.0,-8000.0,27195000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Harrow Health, Inc.",0.2066328,269543520,40.56,9.337017,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,10.14,1630526402,-0.46000004,10.59,10.75,10.113,140476,NGM,us_market,-4.3396225,10.113 - 10.75,10.6,0.0,0.0,8,11,finmb_21993612,NasdaqGM,"Harrow Health, Inc.",USD,271843,135228,5.4900002,1.1806452,4.65 - 11.24,-1.0999994,-0.09786472,4.65,11.24,1620763200,1636369140,1636718400,27.112299,0.374,0.25,-0.13,-78.00001,1.086,8.7748575,1.3651428,0.15557435,8.403551,1.7364492,0.91,,,11.24,4.65,8.77,8.4,271.84k,135.23k,26.58M,,19.24M,11.20%,57.44%,1.86M,6.3,8.69%,7.01%,1.68M,,,,,,0.00%,,,1:5,"Feb 07, 2013","Dec 30, 2020","Mar 30, 2021",18.60%,8.18%,5.20%,45.32%,52.5M,2.02,30.70%,34.41M,6.35M,9.77M,0.37,,32.12M,1.21,20.77M,74.53,4.03,1.09,2.66M,2.38M,Value,37205,Healthcare,125,8,8,"Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.",Nashville,615 733 4730,TN,2,1609372800,1622505600,7,United States,http://www.harrowinc.com,86400,6,102 Woodmont Boulevard,858 345 1745,Drug Manufacturers—Specialty & Generic,Suite 610
t-3,HROW,13436000,26582200,749000,,-260000,-332000,-237000,6954000,4856000,-2847000,-2847000,,-505000,,,,0,8060000,10907000,3204000,2587000,,-260000,-237000,1960000,102889000,34058000,15728000,53000,49454000,26000,200000,-87187000,800000,332000,3902000,13083000,3422000,11252000,30369000,5541000,19164000,2803000,14127000,3841000,5530000,-1923000.0,-337000.0,2966000.0,2966000.0,702000.0,-22000.0,-29000.0,-2651000.0,680000.0,148000.0,-291000.0,-1813000.0,-316000.0,-8000.0,17286000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Harrow Health, Inc.",0.2066328,269543520,40.56,9.337017,15,America/New_York,EDT,-14400000,False,False,PRE,0,2,10.14,1630526402,-0.46000004,10.59,10.75,10.113,140476,NGM,us_market,-4.3396225,10.113 - 10.75,10.6,0.0,0.0,8,11,finmb_21993612,NasdaqGM,"Harrow Health, Inc.",USD,271843,135228,5.4900002,1.1806452,4.65 - 11.24,-1.0999994,-0.09786472,4.65,11.24,1620763200,1636369140,1636718400,27.112299,0.374,0.25,-0.13,-78.00001,1.086,8.7748575,1.3651428,0.15557435,8.403551,1.7364492,0.91,,,11.24,4.65,8.77,8.4,271.84k,135.23k,26.58M,,19.24M,11.20%,57.44%,1.86M,6.3,8.69%,7.01%,1.68M,,,,,,0.00%,,,1:5,"Feb 07, 2013","Dec 30, 2020","Mar 30, 2021",18.60%,8.18%,5.20%,45.32%,52.5M,2.02,30.70%,34.41M,6.35M,9.77M,0.37,,32.12M,1.21,20.77M,74.53,4.03,1.09,2.66M,2.38M,Value,37205,Healthcare,125,8,8,"Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.",Nashville,615 733 4730,TN,2,1609372800,1622505600,7,United States,http://www.harrowinc.com,86400,6,102 Woodmont Boulevard,858 345 1745,Drug Manufacturers—Specialty & Generic,Suite 610
